Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777328 | 0.82 | GPR119 (0.59) | GPR119RETNR1H2PIK3CA | |
| SCHEMBL30796908 | 0.82 | GPR119 (0.46) | GPR119DDB1CRBNRETKDM4E | |
| SCHEMBL22776559 | 0.82 | GPR119 (0.50) | GPR119DDB1CRBNRETPIK3CA | |
| SCHEMBL31271175 | 0.81 | GPR119 (0.58) | GPR119RETHPGDS | |
| SCHEMBL24962301 | 0.80 | GPR119 (0.57) | GPR119RETMAPT | |
| SCHEMBL29731575 | 0.80 | GPR119 (0.58) | GPR119DDB1CRBN | |
| SCHEMBL31271007 | 0.76 | GPR119 (0.56) | GPR119RETMAPTJAK3 | |
| SCHEMBL31270777 | 0.76 | GPR119 (0.53) | GPR119RETJAK3 | |
| SCHEMBL16110048 | 0.76 | GPR119 (0.60) | GPR119JAK1THRBHPGDS | |
| SCHEMBL16110050 | 0.76 | GPR119 (0.60) | GPR119JAK1THRBHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4259144-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GPR119 4361/4885DDB1 333/4885CRBN 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.